8月1日到9日，全球医药交易市场活跃，共签署了24项授权和合作协议。中国医药市场表现尤为突出，共达成13项交易，包括6项出海交易、6项国内交易和1项引进交易。其中最引人注目的交易是默沙东与同润生物就后者CD3xCD19双抗CN201达成的价值13亿美元全球权益授权交易，包括7亿美元的首付款。以首付款计，这是2024年以来最大的一项出海交易。
在全球范围内，共有11项授权和合作协议最终达成。其中的亮点交易是默沙东与第一三共之间就前者的肿瘤资产HPN823达成的合作交易，首付款1.7亿美元。
From August 1 to August 9, a total of 24 licensing and cooperation deals were signed globally, reflecting a dynamic start to the month in the biopharmaceutical sector. The first week of August proved particularly fruitful for the China Biotech Industry, with 13 agreements finalized. These deals include: 6 Out-Licensing Agreements; 1 In-Licensing Agreement; and 6 Domestic Licensing Deals. The standout transaction was the out-licensing acquisition agreement between Curon Biopharmaceutical and Merck & Co. for CN201. This deal, valued at $1.3 billion, included an upfront payment of $700 million, marking it as the largest transaction so far in 2024.
On a global scale, 11 licensing and cooperation agreements were completed during this period. The most significant of these was the agreement between Merck & Co. and Daiichi Sankyo for the oncology asset HPN823, which included a substantial $170 million upfront payment.
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit www.yafocapital.com
Event Name:
